Client News

OKYO Pharma Limited: Change of Auditor
Home / Client News / OKYO Pharma Limited: Change of Auditor

London and New York, N.Y., 1 December, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar dry eye disease market,  announces that the board of directors of the Company (the “Board” or “Directors”), has appointed PKF Littlejohn LLP (“PKF”) as its new independent auditor with immediate effect.

https://www.londonstockexchange.com/news-article/OKYO/change-of-auditor/15738765

​

OPEN AN ACCOUNT

If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.

APPLY NOW

CLIENT AREA

Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

LOGIN

Submit a Comment

Your email address will not be published. Required fields are marked *

Optiva Securities Ltd
118 Piccadilly
London W1J 7NW

Tel +44 (0)20 3137 1902
info@optivasecurities.com
 optivasecurities
@optivalondon
Optiva Securities

KEEP UPDATED

Register to stay updated with the latest news.

    We would like to send you occasional emails about our services and keep you up to date with the latest announcements and news. To join our mailing list, simply click below. You can unsubscribe at any time.

    Optiva Securities Limited is authorised and regulated by the United Kingdom Financial Conduct Authority and are Members of the London Stock Exchange.

    © Copyright Optiva Securities Limited. Registered in England number 3068464
    Share This